The lack of biomarkers for early diagnosis, clinical stratification and to monitor treatment
response has hampered the development of new therapies for amyotrophic lateral sclerosis …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
characterized by the loss of upper and lower motor neurons, which eventually may lead to …

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with largely
unknown pathogenesis that typically results in death within a few years from diagnosis …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of motor
neurons leading to death of the patients, mostly within 2–5 years after disease onset. The …

Background Amyotrophic lateral sclerosis (ALS) is a fatal disorder of the motor neuron
system with poor prognosis and marginal therapeutic options. Current clinical diagnostic …

Background It is unclear to what extent pre-clinical studies in genetically homogeneous
animal models of amyotrophic lateral sclerosis (ALS), an invariably fatal neurodegenerative …

Motor neuron diseases (MNDs) and, in particular, amyotrophic lateral sclerosis (ALS), are a
heterogeneous group of neurologic disorders characterized by the progressive loss of motor …

We use shotgun proteomics to identify biomarkers of diagnostic and prognostic value in
individuals diagnosed with amyotrophic lateral sclerosis. Matched cerebrospinal and …

While unbiased proteomics of human cerebrospinal fluid (CSF) has been used successfully
to identify biomarkers of amyotrophic lateral sclerosis (ALS), high‐abundance proteins mask …

Amyotrophic lateral sclerosis (ALS) is an incurable and rapidly progressive neurological
disorder. Biomarkers are critical to understanding disease causation, monitoring disease …